Monte Rosa Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 33.25 million compared to USD 30.78 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.63 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.33 USD | -2.20% | -8.89% | -5.66% |
Mar. 14 | Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline | MT |
Mar. 14 | Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.66% | 268M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023